At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VERX Vertex, Inc.
Not Yet Opened 12-20 16:00:00 EST
53.53
-0.06
-0.11%
盘后53.53
+0.00+0.00%
19:35 EST
High54.62Low52.00Vol1.86M
Open52.59D1 Closing53.59Amplitude4.89%
Mkt Cap8.35BTradable Cap3.34BTotal Shares155.96M
T/O99.53MT/O Rate2.98%Tradable Shares62.34M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
Motley Fool  ·  00:25
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Motley Fool  ·  12-22 16:30
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Motley Fool  ·  12-21 18:48
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
U.S. Weekly Review｜Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook
Investor’s Business Daily  ·  12-21 09:11
U.S. Weekly Review｜Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
Blockhead  ·  12-21 07:16
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
Vertex Pharmaceuticals Inc. Stock Rises Friday, Still Underperforms Market
Dow Jones  ·  12-21 05:43
Vertex Pharmaceuticals Inc. Stock Rises Friday, Still Underperforms Market
Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
Dow Jones  ·  12-21 05:09
Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
Dow Jones  ·  12-21 05:00
Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
Vertex Pharmaceuticals Gets Expanded FDA Approval for Trikafta
MT Newswires Live  ·  12-21 04:59
Vertex Pharmaceuticals Gets Expanded FDA Approval for Trikafta
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
Reuters  ·  12-21 04:51
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
Vertex announces FDA approval of Alyftrek
TIPRANKS  ·  12-21 04:50
Vertex announces FDA approval of Alyftrek
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Business Wire  ·  12-21 04:46
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex announces FDA exands approval for Trikafta
TIPRANKS  ·  12-21 04:40
Vertex announces FDA exands approval for Trikafta
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
Business Wire  ·  12-21 04:35
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays
Dow Jones  ·  12-21 02:25
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Barclays
Cautious Optimism for Vertex Pharmaceuticals: Suzetrigene’s Potential Amidst Placebo Challenges
TIPRANKS  ·  12-21 02:23
Cautious Optimism for Vertex Pharmaceuticals: Suzetrigene’s Potential Amidst Placebo Challenges
Barclays Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
TIPRANKS  ·  12-21 02:19
Barclays Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Bernstein Adjusts Vertex Pharmaceuticals Price Target to $441 From $506, Maintains Market Perform Rating
MT Newswires Live  ·  12-21 01:37
Bernstein Adjusts Vertex Pharmaceuticals Price Target to $441 From $506, Maintains Market Perform Rating
VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo
Zacks  ·  12-21 00:13
VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo
Channel Therapeutics highlights difference between NaV1.7, NaV1.8
TIPRANKS  ·  12-20 22:16
Channel Therapeutics highlights difference between NaV1.7, NaV1.8

Introduction

Company Name.
Vertex, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vertex, Inc. provides tax technology solutions for retail, communication, leasing, retail trade, wholesale trade, technology, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, analytics and insights, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. Vertex, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Issue price:
--